Clinical trials
Tuberculosis, Pulmonary trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 10 |
| Recruiting | 7 |
| Completed | 5 |
| Not yet recruiting | 3 |
| Active, not recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Beijing Chest Hospital | 6 |
| Huashan Hospital | 4 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 |
| Peking University Third Hospital | 2 |
| Shanghai Jiatan Pharmatech Co., Ltd | 2 |
| Chinese University of Hong Kong | 1 |
| ChromX Health | 1 |
| Fifth Affiliated Hospital, Sun Yat-Sen University | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Global Alliance for TB Drug Development | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tuberculosis, Pulmonary | 27 |
| Tuberculosis | 8 |
| Tuberculosis, Multidrug-Resistant | 5 |
| Pulmonary Disease, Chronic Obstructive | 3 |
| Bronchiectasis | 2 |
| COVID-19 | 2 |
| Lung Diseases, Interstitial | 2 |
| Lung Neoplasms | 2 |
| Acquired Immunodeficiency Syndrome | 1 |
| Asthma | 1 |
Trials
Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.